PerkinElmer Selected by Capital Health of Alberta to Supply Expert Solutions for Expanded Newborn Screening Program



    Tandem Mass Spectrometers, Reagents, and Software Now Used in Canadian
Province's Enhanced Neonatal Screening Program

    WALTHAM, MASS., April 11 /CNW/ - PerkinElmer, Inc. (NYSE:   PKI), a global
leader in Health Sciences and Photonics, today announced a multi-year,
multi-million dollar agreement with Capital Health in Edmonton, Alberta,
Canada, that provides instruments, reagents, software and screening expertise
to enhance its neonatal screening program. The expanded program, which now
includes screening for 17 metabolic conditions in newborns, began
province-wide on April 1, 2007.

    Under the terms of the agreement, signed in the second half of 2006,
Capital Health has purchased tandem mass spectrometry systems, reagent kits
and PerkinElmer's industry-leading Specimen Gate(R) screening software to
expand Alberta's newborn screening for inherited metabolic disorders (IMDs)
including cystic fibrosis. Alberta is the first province in Canada to screen
all newborns for cystic fibrosis.

    "We are pleased to partner with Capital Health to support its
state-of-the-art newborn screening program," said Robert F. Friel, president
of PerkinElmer Life and Analytical Sciences. "PerkinElmer's leading technology
is designed to allow these early detection programs to identify infants at
risk for devastating metabolic disorders, enabling early intervention and
treatment to save lives and improve quality of life."

    Capital Health's Laboratory at the University of Alberta Hospital
provides neonatal screening services for approximately 42,000 babies born in
Alberta annually. Capital Health is one of the largest academic health regions
in Canada.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements relating to estimates and projections of future
earnings per share and revenue growth and other financial results,
developments relating to our customers and end-markets, and plans concerning
business development opportunities. Words such as "believes," "intends,"
"anticipates," "plans," "expects," "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that our
assumptions or expectations will prove to be correct. A number of important
risk factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) our failure to introduce new products
in a timely manner; (2) our ability to execute acquisitions and license
technologies, or to successfully integrate acquired businesses and licensed
technologies into our existing business or to make them profitable; (3) our
failure to protect adequately our intellectual property; (4) the loss of any
of our licenses or licensed rights; (5) our ability to compete effectively;
(6) fluctuation in our quarterly operating results and our ability to adjust
our operations to address unexpected changes; (7) our ability to produce an
adequate quantity of products to meet our customers' demands; (8) our failure
to maintain compliance with applicable government regulations; (9) regulatory
changes; (10) economic, political and other risks associated with foreign
operations; (11) our ability to retain key personnel; (12) restrictions in our
credit agreement; (13) our ability to realize the full value of our intangible
assets; and (14) other factors which we describe under the caption "Risk
Factors" in our most recent annual report on Form 10-K and in our most recent
quarterly report on Form 10-Q and in our other filings with the Securities and
Exchange Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after the
date of this press release.

    Other Information

    Health Sciences end markets include genetic screening, environmental,
service, biopharma, and medical imaging. Photonics markets include sensors and
specialty lighting.

    PerkinElmer, Inc. is a global technology leader driving growth and
innovation in Health Sciences and Photonics markets to improve the quality of
life. The Company reported revenues of $1.55 billion in 2006, has 8,500
employees serving customers in more than 125 countries, and is a component of
the S&P 500 Index. Additional information is available through
www.perkinelmer.com or 1-877-PKI-NYSE.




For further information:

For further information: PerkinElmer, Inc. Investor Contact: Steven
Delahunt, 781-663-5677 or Media Contact: Kevin Lorenc, 781-663-5701

Organization Profile

PERKINELMER, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890